Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer
Nirmesh Patel(King's College London), Andrew Tutt(Institute of Cancer Research), Pierfrancesco Marra(King's College London), Rebecca Marlow(Institute of Cancer Research), Patrycja Gazińska(London Cancer), Elodie Noël(Queen Mary University of London), Erika Francesch-Domenech(King's College London), Jelmar Quist(King's College London), Spiros Linardopoulos(Abzena (United Kingdom)), Anita Grigoriadis(London Cancer), Ana M. Mendes‐Pereira(Institute of Cancer Research), Emanuele de Rinaldis(Target (United States)), Riccardo Ferro(King's College London), Κωνσταντίνος Δροσόπουλος(University of Patras), Daniel Weekes(King's College London), Cynthia Prince(King's College London), Farzana Noor(King's College London), Sumi Mathew(King's College London), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Mamun Rashid(King's College London), Hasan Mirza(London Cancer)
Cited by 57
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k